The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track designation for PET ...

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort. While the rate of ureteral strictures following ureteroscopic laser lithotripsy is low, the incidence ...

The phase 3 study design will now be submitted for final review by the agency. Promontory Therapeutics Inc has reported a positive end of phase 2 (EOP2) meeting with the FDA, paving the way for the ...

The shift from radical cystectomy to bladder-sparing treatments is driven by novel therapies and clinical trials for NMIBC. Defining BCG unresponsiveness remains a challenge, impacting clinical ...

Initial study results may be available as soon as the first half of 2026.

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

Current 2025 guidelines recommend ADT with intensification. Multiple intensification options include abiraterone, darolutamide, and docetaxel. Key clinical trials include ARANOTE, ARASENS, and TITAN.

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

The first successful human bladder transplant was performed by USC and UCLA surgeons, marking a significant medical milestone. The patient, previously on dialysis, showed immediate improvement ...

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD. “This was a multi-institutional study, and the goal was to evaluate the urologist ...

Black men are significantly underrepresented in prostate cancer clinical trials (<5% in most studies). Many trials fail to provide race-specific data. The ARANOTE study achieved 10% representation of ...

According to Adam B. Weiner, MD, a urologist at Cedars-Sinai Medical Center, men should begin prostate cancer screening around ages 50 to 55. Former President Joe Biden has been diagnosed with grade ...